Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

QURE

$23.873.92%0.90

Dopo l'orario di chiusura: 23.10-0.77 -3.23%

Uniqure Nv (QURE)

Date: O: H: L: C: Vol:

Uniqure Nv Borsa (QURE) Ultime notizie

All eyes on UniQure earnings amid pivotal Huntington’s therapy review - Investing.com

How uniQure's(NASDAQ:QURE) Huntington's Disease Gene Therapy Could Become the World's First Disease-Modifying Treatment - Kalkine

uniQure's Gene Therapy BLA for Huntington's Disease Gains FDA Pr - GuruFocus

FDA Opens Review of uniQure's Huntington's Gene Therapy, With May 2027 Verdict Date - BigGo Finance

FDA to review uniQure's Huntington's gene therapy, decision due on May 2027 - Reuters

uniQure Huntington’s Gene Therapy Wins FDA Priority Review, Analyst Bullish - uniQure (NASDAQ:QURE) - Benzinga

uniQure stock jumps as FDA accepts Huntington’s therapy filing - Investing.com

uniQure gains FDA priority review for Huntington's gene therapy - Mugglehead Investment Magazine

uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec - TipRanks

FDA accepts uniQure’s Huntington’s disease gene therapy filing By Investing.com - Investing.com India

Form 8K uniQure N.V. For: 2 November By Investing.com - Investing.com Canada

uniQure Announces FDA Acceptance and Priority Review of the - GlobeNewswire

uniQure N.V. (QURE) Stock Price, News, Quote & History - Yahoo! Finance Canada

uniQure N.V. (QURE) Seasonal returns chart - Yahoo Finance UK

uniQure N.V. (UQ1.F) Seasonal returns chart - Yahoo Finance UK

uniQure N.V. (UQ1.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

3 Promising Genomics Stocks to Add to Your Portfolio Now - Zacks Investment Research

uniQure N.V. (UQ1.F) Seasonal returns chart - Yahoo Finance Australia

Earnings Preview: UniQure NV to Report Financial Results Pre-market on November 04 - Moomoo

uniQure N.V. (QURE) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

uniQure to Announce Third Quarter 2026 Financial Results - GlobeNewswire

uniQure to Announce Third Quarter 2026 Financial Results - Yahoo Finance

uniQure N.V. Estimates – NASDAQ:QURE - TradingView

QURE Assumes Buy Rating by UBS -- Price Target Raised to $48 - GuruFocus

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - marketscreener.com

uniQure: The Market Graded The Wrong Exam (NASDAQ:QURE) - Seeking Alpha

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - Yahoo Finance

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT - GlobeNewswire Inc.

uniQure NV (UQ1.SG) Analyst Insights, Price Targets & Recommendations - Yahoo Finance - Yahoo! Finance Canada

uniQure N.V. (QURE) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore

Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next - Yahoo Finance

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE) - Simply Wall Street

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop - Business Wire

uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review

UniQure Shares Fall After Barclays Downgrade - marketscreener.com

Barclays Downgrades UniQure to Equal Weight From Overweight - Moomoo

Uniqure N.v Stock Price Forecast. Should You Buy QURE? - StockInvest.us

Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - STAT

$uniQure NV (QURE.US)$ - Moomoo

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha

uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research

uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance

uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha

EBITDA of uniQure N.V. – HAN:UQ1 - TradingView

Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar

Four-year data raise durability questions for uniQure’s Huntington gene therapy - biocentury.com

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PR Newswire

Simile a QURE

NTLA$11.861.72%

RARE$16.632.02%

KLRA$12.583.54%

URGN$34.400.12%